Correlation of Susceptibility of Cryptococcus neoformans to Amphotericin B with Clinical Outcome
Larsen RA., Bauer M., Pitisuttithum P., Sanchez A., Tansuphaswadikul S., Wuthiekanun V., Peacock SJ., Simpson AJH., Fothergill AW., Rinaldi MG., Bustamante B., Thomas AM., Altomstone R., Day NPJ., White NJ.
<jats:title>ABSTRACT</jats:title><jats:p>Testing of<jats:named-content xmlns:xlink="http://www.w3.org/1999/xlink" content-type="genus-species" xlink:type="simple">Cryptococcus neoformans</jats:named-content>for susceptibility to antifungal drugs by standard microtiter methods has not been shown to correlate with clinical outcomes. This report describes a modified quantitative broth macrodilution susceptibility method showing a correlation with both the patient's quantitative biological response in the cerebrospinal fluid (CSF) and the survival of 85 patients treated with amphotericin B (AMB). The Spearman rank correlation between the quantitative<jats:italic>in vitro</jats:italic>measure of susceptibility and the quantitative measure of the number of organisms in the patient's CSF was 0.37 (<jats:italic>P</jats:italic>< 0.01; 95% confidence interval [95% CI], 0.20, 0.60) for the first susceptibility test replicate and 0.46 (<jats:italic>P</jats:italic>< 0.001; 95% CI, 0.21, 0.62) for the second susceptibility test replicate. The median<jats:italic>in vitro</jats:italic>estimated response (defined as the fungal burden after AMB treatment) at 1.5 mg/liter AMB for patients alive at day 14 was 5 CFU (95% CI, 3, 8), compared to 57 CFU (95% CI, 4, 832) for those who died before day 14. These exploratory results suggest that patients whose isolates show a quantitative<jats:italic>in vitro</jats:italic>susceptibility response below 10 CFU/ml were more likely to survive beyond day 14.</jats:p>